Clinical Trial

Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer

Study acronym: NEOSAMBA
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 4, 2024 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
Phase III randomized clinical trial evaluating the sequencing of anthracyclines and taxanes in neoadjuvant therapy for locally advanced HER2-negative breast cancer.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-09-01; most recent amendment 2024-06-03.
Status change: Not Yet Recruiting → Recruiting 2021-06-14
Trial Details
NCT Number NCT04540692
Lead Sponsor Latin American Cooperative Oncology Group
Collaborators: Grupo Brasileiro de Estudos do Câncer de Mama (GBECAM)
Conditions Breast Cancer
Enrollment 444 participants
Start Date 2021-01-12
Primary Completion 2026-04 (estimated)
Study Completion 2030-08 (estimated)
Updated on ClinicalTrials.gov 2024-06-04